Contrasting AEON Biopharma (AEON) and Its Competitors

AEON Biopharma (NASDAQ:AEON) is one of 1,060 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare AEON Biopharma to related companies based on the strength of its risk, profitability, dividends, valuation, earnings, institutional ownership and analyst recommendations.

Volatility & Risk

AEON Biopharma has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, AEON Biopharma’s competitors have a beta of 3.71, meaning that their average stock price is 271% more volatile than the S&P 500.

Profitability

This table compares AEON Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
AEON Biopharma Competitors	-3,590.11%	-276.96%	-39.10%

Valuation and Earnings

This table compares AEON Biopharma and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
AEON Biopharma	N/A	-$36.63 million	3.61
AEON Biopharma Competitors	$9.58 billion	$147.39 million	-5.42

AEON Biopharma’s competitors have higher revenue and earnings than AEON Biopharma. AEON Biopharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for AEON Biopharma and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0	0	1	0	3.00
AEON Biopharma Competitors	7768	21186	48893	1231	2.55

AEON Biopharma presently has a consensus price target of $5.00, suggesting a potential upside of 669.23%. As a group, “Pharmaceutical preparations” companies have a potential upside of 187.77%. Given AEON Biopharma’s stronger consensus rating and higher probable upside, research analysts clearly believe AEON Biopharma is more favorable than its competitors.

Insider and Institutional Ownership

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 23.5% of AEON Biopharma shares are owned by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

AEON Biopharma beats its competitors on 7 of the 13 factors compared.

AEON Biopharma Company Profile

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.